Trial Profile
Phase III, multi-center, randomized, double blind, placebo-controlled study for treatment of juvenile ankylosing spondylitis with Adalimumab.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 May 2019
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- 04 Oct 2011 Results presented at the 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 29 Aug 2011 New source identified and integrated (German Clinical Trials Register record, DRKS00000071).
- 23 Jul 2011 New trial record